Drug Database
ME

metronidazole (Elyzol / Pernyzol / Elyzol Dental Gel)

✓ Approved

Pfizer, Inc. · 小分子 · 小分子

什么是 metronidazole?

metronidazole 是一种小分子,由Pfizer, Inc.研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Elyzol, Pernyzol, Elyzol Dental Gel
公司Pfizer, Inc.
药物类别小分子
给药途径Topical
状态Approved

治疗适应症

metronidazole 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsPeriodontitis✓ Approved

相关研究文献

PubMedBMC oral health2026-11-19

Oral multi-niche microbiota and age stratification: a novel strategy for precision screening of periodontitis.

Chen Yinan Y, Mei Enhua E, Zhang Wei W, Wang Yan Y et al.

Periodontitis is a prevalent chronic inflammatory disease driven by oral microbiota dysbiosis, with profound oral and systemic impacts that impair healthy aging. Conventional periodontal assessment requires calibrated clinical examination, is time-consuming, and may cause discomfort or bleeding on probing, which limits its scalability for community-based screening. Microbiota-based strategies therefore show promise for accessible screening; however, the roles of oral niche heterogeneity and age-related microbial shifts remain unclear. A total of 120 participants were classified into low-risk/non-periodontal (NP, n = 67) and high-risk/periodontal (P, n = 53) groups according to a CPI-based index-tooth periodontal risk screening protocol combined with panoramic radiographic assessment. Easily accessible oral samples (saliva, supragingival dental plaque, and tongue coating) were collected for 16S rRNA gene sequencing. Bioinformatic analyses and machine-learning models were used to evaluate diagnostic efficacy, with age stratification (< 50 years vs. ≥ 50 years). Age differed significantly between the NP and P groups in the overall cohort (p = 0.004, t test). After age stratification, no significant within-stratum age differences were observed between the two periodontal groups (< 50 years: p = 0.122; ≥ 50 years: p = 0.948). Non-age-stratified exploratory models showed moderate but variable discriminatory performance, with LOOCV AUCs ranging from 0.616 to 0.740. After age stratification, the niche-specific models showed moderate and relatively consistent performance, with LOOCV AUCs ranging from 0.759 to 0.786 in the < 50-year stratum and from 0.749 to 0.760 in the ≥ 50-year stratum. Although several age-stratified models showed numerically higher AUCs than the corresponding non-age-stratified models, this apparent improvement should be interpreted cautiously because of the reduced subgroup sample sizes. Pairwise DeLong tests showed no statistically significant AUC differences among saliva, supragingival dental plaque, and tongue coating in either the non-age-stratified or age-stratified analyses. Accounting for age-related microbial variation may contribute to more consistent performance of microbiota-based periodontal screening models. However, the three accessible oral niches showed comparable moderate performance, and no single niche demonstrated statistically significant superiority. These findings are preliminary and require validation in larger, multicenter cohorts with independent external validation.

PMID 43052970
阅读全文 →
PubMedBMC oral health2026-11-19

Impact of periodontal inflamed surface area on peri-implant mucositis: a retrospective cohort study.

Yang Ze Z, Deng Jiaqi J, Miao Lei L, Deng Yu Y et al.

To evaluate the association of periodontal inflamed surface area (PISA) and pan-immune-inflammation value (PIV) on the hazard of peri-implant mucositis in patients with severe periodontitis. This retrospective cohort study included implants in patients with severe periodontitis, classified as peri-implant health or mucositis based on clinical and radiographic assessments. Time to first occurrence of peri-implant mucositis characterized by bleeding on probing (BOP) during follow-up of up to 5 years served as the primary endpoint. Cox regression adjusted for patient clustering was performed to examine associations of PISA0, PISA1, and PIV0 with this outcome. Secondary exploratory analyses involved restricted cubic spline (RCS) analysis, maximum log-rank threshold determination, and subgroup stratification. A total of 93 partially edentulous patients with 205 implants were included. Multivariate analysis identified PISA1, but not PISA0, as an independent predictor. A higher PISA1 exceeding the threshold of 447.8 mm2 identified high-risk implants, which exhibited a 3.29-fold greater hazard of mucositis (P < 0.001). High PISA1 remained associated with a greater hazard in both low and high PIV0 (P < 0.05), whereas interaction tests for age, gender, and PIV0 were not significant (P > 0.05). Preoperative PISA, but not initial PISA, was associated with peri-implant mucositis. PISA may help quantify residual periodontal inflammatory burden before implant placement. However, the proposed threshold of 447.8 mm2 and PIV-related findings require further external validation.

PMID 43052930
阅读全文 →
PubMedCNS drugs2026-11-19

Incidence and Factors Associated with Newly Recorded Database-Defined Central Nervous System-Related Diagnoses During and Shortly After Metronidazole Therapy: A Large-Scale Japanese Hospital-Based Administrative Claims Database Study.

Takada Keisuke K, Imai Shungo S, Enoki Yuki Y, Igarashi Yuki Y et al.

Metronidazole (MNZ) is widely used to treat anaerobic and protozoal infections. However, evidence regarding the factors associated with newly recorded, database-defined central nervous system (CNS)-related diagnoses during or shortly after MNZ therapy remains limited. This study evaluated the incidence of newly recorded, database-defined CNS-related diagnoses during and shortly after MNZ therapy and identified the associated factors using a Japanese hospital-based administrative claims database. This retrospective cohort study used the JMDC hospital-based administrative claims database from April 2014 to August 2022. Adults prescribed oral or injectable MNZ were included. The primary outcome was a newly recorded, database-defined CNS-related diagnosis during the risk period after MNZ initiation. Prespecified factors were evaluated using conventional and Firth-penalized Cox proportional hazards regression. Among 58,195 patients, 59 (0.1%) had a newly recorded, database-defined CNS-related diagnosis, including 52 coded as R26.8 (unsteadiness on the feet). Age ≥ 60 years (adjusted hazard ratio [HR] 4.18; 95% confidence interval [CI] 1.70-10.30), female sex (adjusted HR 1.96; 95% CI 1.16-3.31), and renal failure (adjusted HR 1.93; 95% CI 1.08-3.47) were significantly associated with the outcome. In contrast, liver disease and initial daily MNZ dose > 1500 mg/day showed no significant associations. This study estimated the incidence of newly recorded, database-defined CNS-related diagnoses during and shortly after MNZ therapy and identified age ≥ 60 years, female sex, and renal failure as associated factors in the primary Cox regression analysis. Age ≥ 60 years showed the most consistent association across the sensitivity analyses, whereas the associations with female sex and renal failure were less precise in some analyses. However, these findings do not establish causality or a dose threshold.

PMID 43052617
阅读全文 →
PubMedOral diseases2026-11-19

The Central Role of O-GlcNAcylation in Regulating Macrophages in the Pathogenesis of Periodontitis.

Wang Qingqing Q, Wnag Xianglong X, Wang Yuqiao Y, Jiang Xiaohui X

Periodontitis is a chronic inflammatory disease initiated by dental plaque biofilm, characterized primarily by dysregulated host immune-inflammatory responses and progressive alveolar bone resorption, in which the dynamic M1/M2 polarization of macrophages serves as a pivotal regulatory factor. O-GlcNAcylation is a nutrient-sensitive post translational modification, and the relationship between O-GlcNAcylation and periodontitis needs further elucidation. This article systematically reviews recent advances concerning the regulatory role of O-GlcNAcylation in macrophage-mediated periodontitis pathogenesis. Particular emphasis is placed on the bidirectional dose and site-specific effects of O-GlcNAcylation on macrophage polarization. In addition, the molecular mechanisms underlying pathological O-GlcNAcylation-mediated aggravated alveolar bone loss in diabetes-associated periodontitis are summarized. Existing evidence identifies O-GlcNAcylation as a critical molecular hub linking metabolic derangements to periodontal osteoimmune destruction: it either potentiates M1-like pro-inflammatory responses and osteoclastogenesis, or facilitates M2-like reparative phenotypes and periodontal bone regeneration. In diabetes-associated periodontitis, aberrantly elevated O-GlcNAcylation significantly accelerates alveolar bone loss by enhancing inflammatory signaling and suppressing bone formation. O-GlcNAcylation lays novel theoretical foundations and translational strategies for precision immuno-metabolic therapy of periodontitis, especially in patients complicated with metabolic syndrome.

PMID 43053502
阅读全文 →
PubMedTissue engineering. Part B, Reviews2026-11-19

Janus Membranes for Guided Bone Regeneration: A Data-Driven Critical Review and Translational Perspectives.

Yang Zaiwen Z, Chen Shulai S, Suo Jiayao J, Hao Chunbo C et al.

Asymmetrical (Janus) membranes have attracted increasing attention in guided bone regeneration (GBR), yet the field's knowledge structure, developmental trajectory, and barriers to clinical translation remain unclear. This review combines bibliometric analysis with critical evaluation to characterize the research landscape and identify priorities for translational development. Publications on Janus membranes for GBR from 2000 to 2025 were retrieved from the Web of Science Core Collection, yielding 270 core articles. CiteSpace was used to identify research hotspots, developmental trends, and emerging frontiers. Bibliometric findings were integrated with a critical narrative evaluation of current research paradigms and translational limitations. Research showed low output through 2015, followed by a rise to 12-14 publications annually during 2016-2018 and accelerated growth after 2019, with publications peaking at 37 in 2024. Three major research themes emerged: (i) fabrication of bilayer/Janus structures, predominantly by electrospinning; (ii) functionalization with hydroxyapatite, bioactive glass, and antibacterial components; and (iii) applications in periodontal repair and bone regeneration. Rather than representing a simple replacement for established barrier membranes, Janus designs remain largely supported by in vitro and small-animal evidence. Critical analysis identified three major translational bottlenecks: the transition from discrete bilayers to biomimetic gradients, from static release to dynamic responsiveness, and from passive biocompatibility to active immune regulation. Janus membrane research is evolving from structural biomimicry toward functional integration, but a substantial translational gap remains between laboratory-level multifunctionality and clinical application. Future development should adopt design-for-translation (DfT) principles early, with greater attention to clinically relevant indications, scalable manufacturing, surgical operability, and predictive evaluation.Impact StatementJanus-guided bone regeneration membranes are discussed more often than they are used. The literature now clusters around electrospun bilayers that combine a barrier face with antibacterial or osteogenic cues. The harder questions are manufacturing consistency, wet handling, and whether small-animal data predict performance in the mouth. After mapping 270 papers, we argue that the next step is not another multifunctional prototype, but a narrower design matched to one indication and tested in a sequence that a surgical and regulatory team can follow.

PMID 43053557
阅读全文 →
PubMedClinical oral investigations2026-11-19

Intra-sulcular compound chamomile and lidocaine hydrochloride gel for procedural pain during ultrasonic scaling: a randomized, single-blind, split-mouth, sham-controlled superiority trial in adults with plaque-induced gingivitis.

Tang Rong R, Yin Tingting T, Liang Jia J, Wang Ruijie R et al.

This study aimed to evaluate whether intra-sulcular application of a compound chamomile and lidocaine hydrochloride gel (Kami-Gel) reduces procedural pain during ultrasonic supragingival scaling in adults with plaque-induced gingivitis compared with a sham procedure. A single-center, randomized, single-blind, split-mouth, sham-controlled superiority trial was conducted involving 114 adults with plaque-induced gingivitis. Participants received a sequential split-mouth treatment. The test side received intra-sulcular application of Kami-Gel, while the control side received a sham application (mimicked injection). The primary outcome was procedural pain intensity measured on a 0-10 Visual Analog Scale (VAS). Secondary outcomes included the number of pain complaints, procedural duration, patient satisfaction, and plaque index (PI). Safety was assessed immediately and at 24 h. All 114 participants completed the study. Median VAS score was significantly lower in the test group (1.7 [IQR: 0.62-2.58]) than the control group (4.1 [IQR: 2.42-5.7]), with an estimated treatment difference of - 2.35 (95% CI: -3.0 to - 1.7)-the upper limit of which fell below the pre-specified superiority margin of - 1.2, confirming superiority (P < 0.001). The test group also demonstrated significantly fewer pain complaints (median 0 vs. 1), shorter procedural duration (median 10 vs. 12 min), and higher patient satisfaction (all P < 0.001). Post-scaling plaque index was significantly lower in the test group (median 0.75 [IQR: 0.55-0.86] vs. 0.89 [IQR: 0.75-0.96]; P < 0.001), though this difference may reflect improved patient cooperation rather than a direct pharmacological effect. No adverse events were reported. Intra-sulcular application of compound chamomile and lidocaine hydrochloride gel reduces procedural pain during ultrasonic supragingival scaling compared to a sham procedure. Its use was associated with shorter active scaling time and higher satisfaction. Whether these acute benefits translate to improved long-term periodontal treatment compliance warrants further investigation. Intra-sulcular application of compound chamomile and lidocaine gel (Kami-Gel) prior to ultrasonic supragingival scaling reduces procedural pain and was associated with higher patient satisfaction. A lower post-scaling plaque index was observed in the test group, potentially attributable to improved patient cooperation during instrumentation. This safe, non-injectable chairside technique provides clinicians a practical tool to enhance patient comfort during scaling procedures.

PMID 43052462
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多metronidazole